A persistent epithelial defect (PED) of the cornea is challenging in the field of ophthalmology. We present the case of a patient with a PED and its alternative management with umbilical cord serum (UCS). The patient who had the PED in both eyes was treated with UCS for 3 weeks. The epithelial defect healed, and complaints decreased at the end of treatment. UCS is an effective alternative in treating patients with PEDs.
INTRODUCTION
The management of a patient with a persistent epithelial defect (PED) of the cornea is challenging in the field of ophthalmology. It is defined as the absence of improvement in an epithelial defect within 2 weeks with conventional treatment (1) . There are non-surgical and surgical options for the management of PEDs (1) (2) (3) (4) (5) (6) (7) . It is essential that recently introduced alternative therapies gain popularity in the treatment of PEDs refractory to current standard therapies. Herein we presented the preparation and application of umbilical cord serum (UCS) in the management of a PED of the cornea in a patient with graft-versus-host disease.
CASE PRESENTATION
A 65-year-old female who complained of pain, tearing, and stinging in her eyes for more than 2 weeks applied to our department. The patient had undergone bone marrow transplantation 3 years before due to acute myeloid leukemia. She had graft-versus-host disease and underwent immunosuppressive therapy for 2 years. An ophthalmic examination revealed a severely dry eye, a corneal ulcer, and an epithelial defect in both eyes; she received 0.05% topical cyclosporine two times a day, a topical steroid four times a day, and artificial teardrops four times a day in both eyes ( Figure 1 ).Photophobia, blepharospasm, and thinning of the left corneal stroma were also observed. The 0.05% topical cyclosporine A and topical steroid were discontinued. The patient was followed up only with preservative free eyedrops for two weeks instilled every hour when she was awake. Meanwhile, the corneal culture was negative. There was no improvement in her complaints and physical findings. UCS were prepared as defined by Yoon et al. (4) . Umbilical cord blood was collected from patients who underwent elective cesarean section delivery whom laboratory tests were negative for hepatitis B and C and human immunodeficiency viruses at the 8 th and 36 th gestational week of pregnancies after obtaining informed consent. Blood samples were obtained from the umbilical vein. Each sample was kept at room temperature for clotting for approximately 2 h. Serum was isolated following centrifugation at 3000 ×g for 15 min and was diluted to a 20% concentration with balanced salt solution (BSS, Alcon Laboratories, Inc. Fort Worth, Texas 76134, USA). UCS were stored in bottles, 10 to 15 mL in volume. The patient was asked to keep the UCS bottle in a refrigerator at 4°C when used and to renew it every week and the unopened UCS bottles were kept in a freezer at -20°C. UCS was instilled 10 times a day for 2 weeks and 6 times a day at the 3 rd week of treatment. In addition, artificial tears were instilled every hour when awake and moxifloxacin eyedrops were instilled four times a day for 3 weeks simultaneously with a 5-10-min interval. The corneal ulcer and epithelial defect healed in both eyes after 3 weeks of instilling UCS. Leucoma and corneal neovascularization on the left eye corneal surface were observed (Figure 2) .
DISCUSSION
There are several treatment modalities for treating PEDs (2). UCS and autologous serum (AS) have been gaining popularity in recent years due to their efficacy and easy application. Both contain growth factors such as substance P, insulin-like growth factor-1, and nerve growth factor for promoting corneal epithelial migration (5) . In addition, both mainly contain epidermal growth factor, vitamin A, transforming growth factor-beta, and other growth factors and neuropeptides in different concentrations that can facilitate proliferation, migration, and differentiation (4).
Some of the disadvantages in the treatment of PEDs with UCS are blood-borne infections missed in laboratory tests, infections in the window period, and contamination of UCS during preparation, transport, or storage; these might result in mild-to-serious local or systemic infections. AS might be safer than UCS in terms of blood-borne infections, but the probability of infections due to contamination using AS might be the same as that using UCS.
Umbilical cord serum is good option in patients who are not ideal candidates to receive AS such as systemically ill patients or patients with excess pro-inflammatory cytokines in serum such as graft-versus-host disease and Sjögrens syndrome (1, 6) . In addition, UCS has been shown to be more effective in the healing of PEDs (7).
